ReviewClinical microbiology reviews2007
Helicobacter pylori detection and antimicrobial susceptibility testing.
Review in Clinical microbiology reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 282 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
282 citing papers in PubMed, 4 syntheses or guidelines pooled it, 711 citations in OpenAlex.
- Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2022Pooled it
- A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Guideline
- Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.The Cochrane database of systematic reviews · 2016Pooled it
- The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America.The American journal of gastroenterology · 2014Pooled it
- Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial).PloS one · 2023Trial
- Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study).Asian Pacific journal of cancer prevention : APJCP · 2020Trial
- Trial
- High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015Trial
- High In Vitro Activity of the Novel Pleuromutilin Antibiotic, Lefamulin, on ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Review
- Efficacy and Safety of Tegoprazan inPharmaceuticals (Basel, Switzerland) · 2026Review
- High Levels ofMicroorganisms · 2026Article
- Assessment ofMicroorganisms · 2026Article
- Antibiotic resistance and associated gene mutations ofFrontiers in cellular and infection microbiology · 2026Article
- PredictingInfection and drug resistance · 2026Article
- Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study.The Lancet. Microbe · 2026Observational
- VTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2026Article
- Site-stratified global oralJournal of oral microbiology · 2026Review
- Review
- Agave Fructans as a Carbon Source to Develop a Postbiotic-Based Strategy for the Prophylaxis and Treatment ofInternational journal of molecular sciences · 2025Article
222 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of Helicobacter pylori in 1982 was the starting point of a revolution concerning the concepts and management of gastroduodenal diseases. It is now well accepted that the most common stomach disease, peptic ulcer disease, is an infectious disease, and all consensus conferences agree that the causative agent, H. pylori, must be treated with antibiotics. Furthermore, the concept emerged that this bacterium could be the trigger of various malignant diseases of the stomach, and it is now a model for chronic bacterial infections causing cancer. Most of the many different techniques involved in diagnosis of H. pylori infection are performed in clinical microbiology laboratories. The aim of this article is to review the current status of these methods and their application, highlighting the important progress which has been made in the past decade. Both invasive and noninvasive techniques will be reviewed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.